GPC sobre Ansiedad - GuíaSalud

Behavioral Therapy Supplemented with telephone calls. The American
Journal of Psychiatry. 2006; 163(12):2119-2125.
191. Mihalopoulos C, Kiropoulos L, Shih ST, Gunn J, Blashki G, Meadows
G. Exploratory economic analyses of two primary care mental health
projects: implications for sustainability. Med J Aust. 2005; 183(10
Suppl):S73-6.
192. Saeed SA, Bloch RM, Antonacci DJ. Herbal and Dietary Supplements
for Treatment of Anxiety Disorders. American Family Physician. 2007;
76(4):549-56.
193. Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: systematic
review and meta-analysis. Journal of Clinical Psychopharmacol.
2000; 20:84-9.
194. Pittler MH, Ernst E. Extracto de Kava para el tratamiento de la ansiedad
(Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus,
2007 Número 2. Oxford: Update Software Ltd. Disponible en: http://
www.update-software.com. (Traducida de The Cochrane Library, 2007
Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
195. Connor KM, Payne V y Davidson JR. Kava in generalized anxiety disorder:
three placebo-controlled trials. International Clinical Psychopharmacology.
2006; 21(5):249-53.
196. Boerner RJ, Sommer H, Berger W, Kuhn U, et al. Kava-Kava extract LI
150 is as effective as Opipramol and Buspirone in General Anxiety disorder
– an 8 week, randomized, double-blind multi-centre clinical trial
in 129 out-patients. Phytomedicine. 2003; 10 Suppl 4: 38-49.
197. Lehrl S. Clinical efficacy of kava extract WSR 1490 in sleep disturbances
associated with anxiety disorders - Results of a multicenter, randomized,
placebo-controlled, double-blind clinical trial. Journal of Affective Disorders.
2004; 78(2):101–110.
198. Cairney S, Maruff P, Clough A R, Collie A, Currie J and Currie BJ. Saccade
and cognitive impairment associated with kava intoxication. Human
Psychopharmacology. 2003; 18(7):525-33.
199. Barnes J. Quality, efficacy and safety of complementary medicines: fashions,
facts and the future. Part II: Efficacy and safety. British Journal of
Clininical Pharmacology. 2003; 55(4):331-340.
200. Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration.
Kava-containing dietary supplements may be associated
with severe liver injury. Acceso 19 octubre de 2007. Disponible en: http://
www.cfsan.fda.gov/~dms/addskava.html.
ORDEN SCO/190/2004, de 28 de enero, por la que se establece la lista
201.
de plantas cuya venta al público queda prohibida o restringida por razón
GPC PARA EL MANEJO DE PACIENTES CON TRASTORNOS DE ANSIEDAD EN ATENCIÓN PRIMARIA 125